Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Conditions
Interventions
Placebo
RG7774
Locations
68
United States
Arizona Retina and Vitreous Consultants
Phoenix, Arizona, United States
Retina Associates Tucson
Tucson, Arizona, United States
Win Retina
Arcadia, California, United States
Global Research Management
Glendale, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, United States
Retina Consultants of Southern Colorado PC
Colorado Springs, Colorado, United States
Start Date
June 5, 2020
Primary Completion Date
July 19, 2023
Completion Date
July 19, 2023
Last Updated
September 25, 2024
NCT07296952
NCT07351786
NCT03713268
NCT03135327
NCT06782997
NCT06305416
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions